HB 125 Louisiana House · 2025 Regular Session

TECHNOLOGY: Provides for the protection, storage, and access of genomic information (EN SEE FISC NOTE GF EX)

HB 125 amends Louisiana law to prohibit insurers from using genetic research or testing participation (including clinical research) when deciding coverage, premiums, or other underwriting decisions, unless the genetic results are in the individual's medical record or explicitly provided by them. This directly affects individuals who have undergone genetic testing and insurers who underwrite health coverage. The bill replaces existing language to clarify that insurers cannot consider participation in genetic research as a factor in coverage decisions, while allowing use of documented genetic results. It is currently pending after passing committee unanimously (16-0) and awaiting further legislative action.

Issues: ✓ Healthcare ✓ Technology

Bill status signed all 5 stages cleared

Introduction

Mar 2025

Committee Review

Jun 2025

House Passage

Jun 2025

Senate Passage

Jun 2025

Signed into Law

Jun 2025

Introduced Mar 25, 2025 Signed Jun 11, 2025

Maddy AI version diff · 4 comparisons

What changed between versions

HB125 Original → HB125 Act 244 · 3 edits

MINOR

The bill was renamed from the 'Louisiana Genomic Security Act' to the 'Louisiana Human Genomic Security Act' to clarify its focus on human genetic data. The most significant substantive change is the addition of a new definition for 'foreign adversary company,' which explicitly includes entities that receive more than 50% of their revenue from foreign adversary nations, expanding the scope of prohibited entities beyond just those domiciled or headquartered abroad. The core prohibitions against using specific foreign technology and storing data in foreign adversary countries remain largely intact, but the new revenue-based definition tightens the criteria for what constitutes a prohibited entity.

Scope change

The scope of prohibited entities was expanded to include companies that are not necessarily domiciled in a foreign adversary country but derive more than 50% of their revenue from such countries.

DEFINITION

Added a new definition for 'foreign adversary company' to include entities receiving over 50% of revenue from foreign adversaries, broadening the list of banned entities.

Updated several definitions to specify 'human' genetic information, clarifying the bill's focus on human rather than general genetic data.

SCOPE

Changed the short title from 'Louisiana Genomic Security Act' to 'Louisiana Human Genomic Security Act' to emphasize the specific type of data protected.

Floor votes · Senate Jun 8, 2025 · House May 12, 2025

How they voted

28–7

Passed · 2 other

Total votes 37

Jun 8, 2025

D Democratic11

3 Yea 7 Nay 1

63% Nay

R Republican26

25 Yea 1

96% Yea

Vote distribution

All Yea All Nay Mixed No data

Full legislative history

Actions timeline

Total actions

Key actions

Committee

Jun 9, 2025

Lower · Passed

Read by title, roll called, yeas 82, nays 19, Senate amendments concurred in.

lower

Jun 8, 2025

Upper · Passed

Rules suspended. The amended bill was read by title, passed by a vote of 30 yeas and 7 nays, and ordered returned to the House. Motion to reconsider tabled.

upper

Jun 4, 2025

Upper · Passed

Reported with amendments. Rules suspended. Committee amendments read and adopted. Read by title and referred to the Legislative Bureau.

upper

May 12, 2025

Lower · Passed

Read third time by title, amended, roll called on final passage, yeas 80, nays 14. Finally passed, title adopted, ordered to the Senate.

lower

May 6, 2025

Lower · Passed

Reported with amendments (16-0).

lower

Apr 14, 2025

Committee

Read by title, under the rules, referred to the Committee on Commerce.

lower

Mar 25, 2025

Committee

Under the rules, provisionally referred to the Committee on Commerce.

lower

1 primary · 0 co-sponsors